Kornimate/medical-research-clean huggingface dataset:
evolution of coronavirus disease 2019 (covid-19) patients in extremadura

Conditions: Coronavirus Disease 2019

Summary: at the end of january 2020, the international community was informed of the presence of a new viral disease that started in wuhan (china) and spread rapidly throughout the world. the identified virus belonged to the coronavirus family (sars-cov-2) and the disease was named covid-19. today there are more than 2 million people diagnosed in spain and more than 40 thousand in extremadura. the partial knowledge about the development, evolution of the affected citizenship and their prognosis both early and late makes it necessary to analyze in depth their global and particular characteristics. we will carry out a multicenter, observational, descriptive, cross-sectional and longitudinal study of patients diagnosed with sars-cov-2 virus infection in the community of extremadura to determine the effectiveness of drug treatments and the clinical and evolutionary characteristics of these patients and the different factors that may influence its evolution.

epidemiological, socio-sanitary, clinical, analytical and radiological data will be collected retrospectively and prospectively from all patients diagnosed with covid-19 without hospital admission in our community from the start of the pandemic and for one year from the start of the study. these data will be obtained mainly from the clinical history and collected in the data collection notebooks and electronic base designed for the study for subsequent analysis. the data collection period will be one year, estimating a sample of 5,000 patients. in addition, patients included in the study prospectively will be asked for consent to collect a blood sample for freezing and storage in the biobank of extremadura and subsequent use to determine biomarkers and genetics. the present study will be carried out in accordance with the observational national post-authorization study (epa) for medicines for human use proposed by valdecilla health research institute (idival), the main objective of which is to determine the effectiveness of the pharmacological treatments currently used in covid-19.

Eligibility criteria:
inclusion criteria: * patients of any age and sex, including minors and pregnant women. * patients diagnosed with sars-cov2 infection according to the clinical and microbiological criteria established by the health authorities and clinical practice (these can be modified based on the technical document "clinical management of covid-19" of the ministry of health) who require or not hospitalization and who receive or not specific pharmacologic treatment for the sars-cov2 infection. exclusion criteria: * patients who do not give their informed consent to participate in the study.

Keywords: patients diagnosed with coronavirus disease 2019 clinical characteristics of coronavirus disease 2019 clinical evolution of coronavirus disease 2019 effectiveness of drug treatment for coronavirus disease 2019
normal values of ambulatory 24-hour oesophageal ph-impedance monitoring in an indian cohort of participants

Conditions: GERD (Gastroesophageal Reflux Disease)

Summary: this study aims to determine normal 24-hour ph-impedance monitoring values, including acid exposure time (aet), in healthy indian adults. it will help improve gerd diagnosis in india by providing population-specific data. the study will also explore how diet, body position, and nighttime reflux affect acid exposure. healthy volunteers aged 18 and above will be monitored for 24 hours.

this prospective study aims to establish normal 24-hour ambulatory ph-impedance monitoring values, including acid exposure time (aet), in healthy indian volunteers. with an estimated gerd prevalence of 8-10% in india, current diagnostic criteria, such as the lyon consensus cut-off of 6%, may not be suitable for the indian population due to differences in aet. the study will investigate the normative values of aet in healthy individuals and examine how factors such as diet, body position, and nocturnal reflux influence acid exposure and reflux episodes. by determining these standard values, the study seeks to enhance the accuracy of gerd diagnosis in india and improve understanding of reflux patterns specific to the indian population. participants will be healthy adults aged 18 and above, without gastrointestinal symptoms or major systemic diseases. the study will be conducted as a single-centre, 24-hour monitoring protocol.

Eligibility criteria:
inclusion criteria: * adult 18-50 years of age * no gastro-intestinal symptoms * no past gi or thoracic or spine surgery * not on any medications * no history of recent alcohol intake (0 drinks in the past 1 month) * non smoker * normal bmi (18.5-22.9) exclusion criteria: * any diagnosed systemic or organ specific disease (liver/kidney/heart/neurological disease, dm/htn/thyroid disease/ connective tissue disorder/inflammatory bowel disease/ irritable bowel syndrome) * gerd symptoms/ functional dyspepsia * pregnant women or breast-feeding women * helicobacter pylori infection

Keywords: 24- hour ph impedance monitoring gerd acid exposure healthy volunteers indian cohort reflux episodes
group-based mindfulness for chronic pain in the primary care setting

Conditions: Chronic Pain; Back Pain

Summary: the purpose of this pragmatic clinical trial (pct) research is to determine whether a group-visit approach modeled on mindfulness-based stress reduction can improve function for persons with chronic low back pain. this will be done by an embedded pct within the evidence-based "optimum" (optimizing pain treatment in medical settings using mindfulness) program.

the research will be conducted with three health care system (hcs) sites: boston medical center, ma, a safety net health system; upmc, pittsburgh, pa, a large health system; and piedmont health services, nc, a network of federally funded health centers in partnership with the university of north carolina (unc), chapel hill. as per nih protocol for the funding, the first 12 month (phase 1) of this pct will be a pilot to plan and test the group-based mindfulness program for chronic pain program in each of the three sites with 5 participants/site. once completed the phase 2 will be conducted to integrate and test the group-based mindfulness program compared to standard of care for patients with chronic low back pain (clbp) in the primary care setting at each collaborating site. eligible consenting participants will be randomized to either: the primary care providers (pcp) usual care group, or the group with both pcp usual care and the 8 weeks mindfulness clinical pain group. participants will be asked to complete baseline and follow-up surveys about pain, function, pain medicine use, mood and anxiety symptoms, and quality of life. the surveys will take up to an hour to complete.

Eligibility criteria:
inclusion criteria: * age ≥ 18 * chronic low back pain, which is pain that persists for at least 3-months and has resulted in pain on at least half the days in the past 6 months * a score ≥ 3 on the peg * willing and able to provide online or telephone informed consent * speak english as the intervention manual is currently written in english exclusion criteria: * do not meet the above inclusion criteria * red flags- recent (past month) worsening of pain, unexplained fever, unexplained weight loss * pregnancy * metastatic cancer * first-degree relatives (parents, siblings, child) of someone who has participated or is participating in the optimum study * members of the same household * not a patient at a participating clinic or persons not planning to continue as a patient at a participating clinic for 12 or more months

Keywords: mindfulness-based stress reduction medical group visits primary care setting
pilot study for healing and safety outcomes in gingival recession

Conditions: Gingival Recession

Summary: prospective, randomized, within subjects-controlled design

the objective of this trial is to evaluate clinical healing outcomes of microsurfaced cadaveric adm (markman biologics) used in sites with \< 1 mm of attached gingiva requiring soft tissue grafting without root coverage as compared to control cadaveric adm (alloderm, lifecell) over 180-day post-op period. during the treatment period, each site will be monitored for soft tissue healing and augmentation of keratinized tissue width. all subjects will be seen at post-op day 7, 14, 30, 90, and 180.

Eligibility criteria:
inclusion criteria: 1. signed informed consent by patient or legally authorized representative (lar) 2. patients with ≥2 non-adjacent teeth in the same jaw presenting with ≤ 1mm attached gingiva that requires soft tissue grafting without the need for root coverage 3. patients with good oral hygiene as indicated by presence of minimal plaque and absence of material alba and calculus. 4. ≥ 18 and ≤ 75 years of age 5. sexually active subjects (both men and women) who agree to use acceptable contraceptive methods for the duration of the study. exclusion criteria: 1. vestibule depth \<7mm from the base of recession 2. systemic condition, such as uncontrolled diabetes mellitus, hiv, cancer, or bone metabolic disease that could compromise wound healing 3. treatment with systemic corticosteroids, immunosuppressive agents, radiation therapy, or chemotherapy within 2 months of enrollment in the study 4. acute infection lesions in intended grafting sites 5. received intravenous or intramuscular bisphosphonates 6. tobacco use within 3 months of enrollment or for the duration of the study 7. only molar teeth suitable for soft tissue grafting (molars may be treated but not assigned as the study tooth) 8. miller grade ≥2 mobility on grafting sites or adjacent teeth 9. known hypersensitivity to bovine collagen or iodine (shellfish allergy) 10. previous treatment with an advanced biologic at sites selected fro grafting or the adjacent teeth 11. pregnant or nursing female subjects; women of child-bearing potential must have a negative urine pregnancy test. 12. developmental disability/significant psychological disorder that in the opinion of the investigator could impair the subject's ability to provide informed consent, participate in the study protocol or record study measures, including untreated schizophrenia, bipolar disorder and psychiatric hospitalization within the last 2 years. 13. active alcohol or substance abuse (including marijuana, thc, cbd oils and products) in the opinion of the investigator that could impair the subject's participation in the study. 14. any medical condition or co-morbidity that in the opinion of the investigator, would prevent successful participation in the study 15. known allergies to cefoxitin, gentamycin, lincomycin, polymyxin b, vancomycin, or any antibiotic in these same classes. 16. known allergy to polysorbate 20
effectiveness of a socio-community health intervention on pre-frailty in older adults

Conditions: Frail Elderly Syndrome

Summary: the objective of this study is: to evaluate the effectiveness of a health intervention with a socio-community approach on frailty in older adults with pre-frailty. specific objectives: to characterize the study population according to sociodemographic and clinical variables. to evaluate the effect of the intervention on the functionality domain at 3 and 6 months. to evaluate the effect of the intervention on the cognitive-emotional domain at 3 and 6 months. to evaluate the effect of the intervention on the socio-community domain at 3 and 6 months. to evaluate the effect of the intervention on frailty in older adults. to determine the proportion of participants hospitalized during the study period. to determine the proportion of participants who visited the emergency room during the study period. to determine the proportion of participants in long-term care facilities. to determine the proportion of adverse events associated with the intervention. study hypothesis the mean frailty score pre-intervention is equal to the mean frailty score post-intervention. the mean frailty score pre-intervention is different from the mean frailty score post-intervention.


Eligibility criteria:
inclusion criteria: * individuals ≥ 60 years old classified as pre-frail in the last 3 months and documented in their medical history. * individuals who meet the requirements and provide voluntary informed consent for their participation. * individuals available to remain in bogotá d.c. during the study period. exclusion criteria: * individuals receiving care at community-focused medical centers. * individuals attending community dining programs, physical activity programs, community groups, care blocks, volunteering, or other related activities. * individuals who have experienced falls in the last 6 months with clinical consequences (hospitalization, fractures, traumatic brain injury). * individuals with a clinical history of moderate cognitive impairment, neurodegenerative diseases (e.g., parkinson's disease), and/or neuro-musculoskeletal disorders, active cancer, end-stage renal disease, unstable ischemic heart disease, uncontrolled arrhythmias, severe aortic stenosis, uncontrolled hypertension (\>180/100 mmhg), or advanced heart failure, exacerbation of chronic diseases (copd, heart failure), unrehabilitated severe hearing loss, deafness, or blindness with communication limitations. * acute conditions requiring hospitalization, such as acute myocardial infarction or urinary tract infections. * bone fractures in the last 3 months. * individuals unable to follow instructions or with behavioral changes that hinder their participation in the study. * individuals with severe psychiatric illness that, in the physician's judgment, prevents proper adherence to the study intervention. * institutionalized individuals in long-term care facilities.

Keywords: prefrailty frailty older adults
study of bms-275183 in patients with pretreated locally advanced or metastatic nsclc (non small cell lung cancer)

Conditions: Non-small Cell Lung Cancer

Summary: bms-275183 given orally twice weekly to patients pretreated for locally advanced or metastatic nsclc will show anti-tumor activity in any of the 3 separate cohorts of the patients enrolled: * cohort i: patients previously treated with one taxane containing regimen. * cohort ii: patients previously treated with a platinum based but non-taxane containing regimen. * cohort iii: patients previously treated with both a chemotherapy regimen and one egfr-tki (epidermal growth factor receptor-tyrosine kinase inhibitor) compound. patients in cohorts i and ii should have not been treated with a prior egfr-tki compound. prior treatment with a vegfr (vascular endothelial growth factor receptor) inhibitor compound is allowed for all the patients provided that the vegfr inhibitor is not also an egfr inhibitor.


Eligibility criteria:
inclusion criteria: * men and women, age \>= 18 years * subjects with histologically or cytologically confirmed locally advanced or metastatic nsclc who failed only one prior chemotherapy regimen. exclusion criteria: * concomitant medication with a cytochrome p450 (cyp) 3a4 inhibitor or inducer

Keywords: locally advanced or metastatic non-small cell lung cancer
correlation between regional brain volume and response to donepezil treatment in ad patients

Conditions: Alzheimer's Disease

Summary: this study investigate the relationship between regional brain volume measured by mri and donepezil treatment response in patients with alzheimer's disease.


Eligibility criteria:
inclusion criteria: 1. over 60 years old. 2. probable or possible alzheimer's disease according to the dsm-iv and nincds-adrda. 3. mmse score of 10\~24, cdr of 1\~2. 4. patients didn't take acetylcholinesterase inhibitors 4 weeks before screening. 5. permitted drugs: antipsychiatric drug for bpsd, antidepression drug, tranquilizer, treatment drug for physical disease for example hypertension. exclusion criteria: 1. uncontrolled by donepezil because of adverse events. 2. no longer continuing treatment of donepezil for refuse, drug-drug interaction etc. 3. if they have taken concomitant medication which were not allowed.
efficacy and safety of nva237 in patients with chronic obstructive pulmonary disease (copd)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this study was designed to investigate the efficacy and safety of nva237, a long-acting muscarinic antagonist, in patients with moderate to severe copd.


Eligibility criteria:
inclusion criteria: * male and female patients age 40 years or more * diagnosis of chronic obstructive lung disease (copd) (moderate to severe as classified by the global initiative for copd (gold) guidelines, 2008 * smoking history of at least 10 pack-years * post-bronchodilator forced expiratory volume in 1 second (fev1) \<80% and ≥30% of the predicted normal value * post-bronchodilator fev1/forced vital capacity (fvc) \<0.7 * symptomatic patients, according to daily electronic diary data between visit 2 (day -8) and visit 3 (day 1), with a total score of 1 or more on at least 4 of the last 7 days prior to visit 3 exclusion criteria: * patients who have had a copd exacerbation requiring systemic corticosteroids and/or antibiotics and/or hospitalization in the 6 weeks prior to the first visit * patients who have had a respiratory tract infection within 4 weeks prior to the first visit * patients with concomitant pulmonary disease * patients with diabetes type i or uncontrolled diabetes type ii * any patient with lung cancer or a history of lung cancer * patients with a history of certain cardiovascular co-morbid conditions * patients with a history of asthma or a blood eosinophil count \>600/mm3 or onset of symptoms prior to 40 years * patients with eczema, known high ige levels or a known positive skin prick test * patients participating in the active phase of a pulmonary rehabilitation programme * patients contraindicated for the treatment with anticholinergics, long and short-acting beta-2 agonists or sympathomimetic amines * patients with a history of alpha-1 anti-trypsin deficiency * patients on long term oxygen therapy (\>15hr per day) * other protocol-defined inclusion/exclusion criteria may apply

Keywords: copd
evaluation of a novel infra-red breast imaging system for risk assessment in women at high risk for breast cancer.

Conditions: Breast Cancer

Summary: three-dimensional functional metabolic imaging (3d mira) is a new infrared imaging technology using the real imager 4(ri4) developed by real imaging. this technology generates 3d metabolic maps and based on sophisticated machine learning technology, provides objective risk assessment for the presence of malignant tumor. the procedure is non-invasive, comfortable and does not involve ionizing radiation. moreover, real imaging's 3d functional mira is unaffected by breast density and is therefore ideal for evaluating patients with mammographically dense breasts. the purpose of this clinical study is to assess the ability of this novel technology to detect clinically occult breast cancer in a cohort of women that are at high risk for breast cancer. we hypothesize that the combination of screening mammography and metabolic screening (3d mira) will result in significantly higher breast cancer detection rates.


Eligibility criteria:
inclusion criteria: * female * woman has read, understood and signed the inform consent form * age: 20 years and older * women who are asymptomatic for breast cancer * proven carriers of deleterious brca1 or brca2 mutations or women that were found to have a lifetime risk of developing breast cancer greater or equal to 20% based on tyrer-cuzick, gail or clause risk models * women scheduled to undergo routine mammography and/or us or mri screening exclusion criteria: * women who have had a mammography and/or ultrasound examination performed on the day of the study prior to mira scan * women who had a lumpectomy surgery * women who had undergone mastectomy and/or reconstruction * women who have undergone any type of breast surgery throughout the 6 months preceding the study * women who have had a breast biopsy performed throughout the 10 weeks preceding the study. * women who have a fever on the day of the mira imaging * women who are pregnant * women who are breast-feeding * women who had undergone breast reduction/augmentation
effect of intra-oral photobiomodulation on orthodontic treatment time

Conditions: Malocclusion

Summary: the aim of this study is to determine the effect of orthopulse™, an intra-oral led (light emitting diode) photobiomodulation device, on orthodontic treatment time. this is a double-blinded rct with half the patients receiving treatment from a sham non-functional device, serving as controls, and the other half receiving light therapy treatment from a functional orthopulse™. orthodontic treatment time for the sham-control patients are compared to that of the orthopulse™ patients.


Eligibility criteria:
inclusion criteria: * presence of permanent dentition * eligible and scheduled for full mouth fixed orthodontic treatment. * class i or class ii malocclusion (no more than ½ cusp in class ii) * non-extraction in all quadrants * non-smoker, non-use of chewing tobacco * good oral hygiene * no adjunct treatment such as extra or intraoral appliances * age 12-40 exclusion criteria: * pregnant females * patient is currently enrolled in another clinical study * non-steroidal anti-inflammatory drug (nsaid) use during study (acetominophen acceptable) * periodontally involved teeth * use of bisphosphonates * unerupted erupted teeth * teeth blocked out of alignment and unable to engage initial arch wire

Keywords: photobiomodulation orthodontic treatment malocclusion orthopulse™
behavior brain responses

Conditions: Alcohol Drinking; Drinking Behavior; Physiological Effects of Drugs; Central Nervous System Depression

Summary: to compare responses to acute oral doses of ethanol in healthy young adults who experience mainly stimulant subjective effects from the drug or mainly sedative effects.


Eligibility criteria:
* 21-35 years old * 4-30 alcoholic drinks per week (as reported on phq or tlfb) * no 'flushing' reaction to alcohol * bmi 19-26 * high school education or greater, fluent in english * no night shift work * no current or past year axis i psychiatric disorder including drug/alcohol dependence * no current psychopharmacological treatment * no lifetime adhd or prescription for adhd medication * no abnormal ekg, cardiovascular illness, high blood pressure * no medical condition or pharmacological treatment for which alcohol is contraindicated * not pregnant, lactating, or planning to become pregnant * smoke \<6 cigarettes per day